ALTSTATION.IO

DaVita Inc. (DVA) Stock Analysis

By Nova Skye | AltStation.io | Updated February 07, 2026

Price

$140.54

Change

-5.82%

Market Cap

$9.39B

Avg Volume

1.0M

Company Overview

DaVita Inc. provides kidney dialysis services primarily for patients with chronic kidney failure. Based in Denver, the company operates outpatient dialysis centers across the United States and offers related laboratory services. Their offerings include outpatient, hospital inpatient, and home-based hemodialysis, along with management services for other dialysis centers. Additionally, DaVita provides integrated care, clinical research, and transplant software, positioning itself as a comprehensive provider in the kidney care space.

In terms of competitive positioning, DaVita is a market leader in the U.S. dialysis sector, commanding approximately 35% of the market share. Its extensive network of over 2,800 dialysis centers gives it a notable edge, particularly in operational scale and brand recognition. Key competitors include Fresenius Medical Care and US Renal Care, which are formidable in a market facing pressures from regulatory changes and increasing focus on value-based care. These dynamics could threaten margins, as cost-management strategies and patient outcomes become more scrutinized.

Currently, DaVita is in a phase of strategic pivoting towards integrated care models, seeking to enhance patient outcomes and reduce costs. The company recently announced plans to increase investment in technology and take on risk-based contracts as part of its services. Financially, DaVita has shown resilience, with a revenue growth of about 5% year-over-year in its latest fiscal report, indicating that it is adapting well amidst evolving healthcare demands.

Key Financials

Market Cap

$9.39B

Revenue

$13.64B

EBITDA

$2.75B

Gross Margin

32.2%

Profit Margin

5.5%

Revenue Growth

9.9%

Total Cash

$700.74M

Total Debt

$12.87B

Free Cash Flow

$1.05B

52-Week Price Performance Analysis

Price Statistics

P/E Ratio

14.78

Forward P/E

8.87

Beta

1.01

52-Week High

$178.38

52-Week Low

$101.00

EPS

$9.51

50-Day Avg

$115.24

200-Day Avg

$129.94

Price/Book

-14.80

Technical Analysis

Over the past 52 weeks, DaVita Inc. (DVA) has experienced a downward trend, reflecting an overall decline of 18.8%. Key support levels appear to be around $135, where the price has bounced previously, while resistance is identified at approximately $160, illustrating a significant barrier for upward movement. The chart displays notable patterns, including a potential head-and-shoulders formation, indicating a reversal trend that could be bearish. In recent weeks, there’s been a slight uptrend, suggesting a potential short-term recovery as the stock price has been fluctuating near its support level. Currently at $140.54, DaVita is positioned roughly 5.6% above the 52-week low of $132, which implies that while there may be a slight rebound, the stock remains vulnerable given its recent historical performance and proximity to support levels.

Recent News and Developments

Here are the latest news and developments for DaVita Inc

(DVA) stock from January 31 to February 7, 2026:

1. DaVita Exceeds Q4 2025 Earnings and Revenue Estimates, Provides Strong 2026 Outlook

DaVita Inc. announced robust financial results for the fourth quarter of 2025 on February 2, 2026, surpassing analyst expectations for both earnings per share (EPS) and revenue. The company reported an adjusted EPS of $3.40 and revenues of $3.62 billion, exceeding consensus estimates of $3.24 (or $3.16) and approximately $3.51 billion, respectively. Following this strong performance, DaVita issued an optimistic outlook for fiscal year 2026, projecting adjusted EPS in the range of $13.60 to $15.00, which is above prior market expectations and represents an anticipated 33% growth at the midpoint.

2. DaVita Stock Experiences Significant Rally Post-Earnings, Followed by Pullback

Following the release of its strong Q4 2025 earnings and positive 2026 guidance, DaVita’s stock saw a substantial surge. Shares jumped 25.3% in morning trading on February 4, 2026, with some reports noting a 7-day winning streak and cumulative gains of 41% by February 6, 2026. However, the stock experienced a downturn on February 6, 2026, sliding 4.85% to close at $141.98, as investors began to reassess the rapid rally. The closing stock price on February 6, 2026, was $140.83.

Market Sentiment and Analyst Recommendations

Bull Case

DaVita just crushed Q4 2025 with adjusted EPS of $3.40 versus $3.24 expected, and management is guiding to $13.60-$15.00 for 2026, implying 33% growth at the midpoint. The 9.9% revenue growth is solid for a mature dialysis operator, and at a 14.78 P/E multiple, the stock is cheap relative to that growth trajectory. The company is making smart moves beyond core dialysis with the $200 million Elara Caring investment and the Mozarc Medical joint venture with Medtronic, which positions them in home dialysis and kidney tech where margins could be better. UBS upgraded to Buy with a $190 target, and even the conservative Barclays raised to $158, suggesting institutional money sees real value here. The stock is only 5.6% above its 52-week low, meaning the downside is limited while the upside to analyst targets is 7-34% from current levels.

Bear Case

That debt load is a problem. DaVita is carrying $12.87 billion in total debt against just $700.74 million in cash, leaving minimal cushion if margins compress or dialysis reimbursement rates get cut again. The 52-week chart shows an 18.8% decline and a potential head-and-shoulders reversal pattern, which is a red flag for technical traders. The stock just ripped 41% in a week on guidance that, while strong, now needs execution and the market has front-run a lot of upside already. Healthcare policy risk is real here — dialysis is heavily dependent on Medicare reimbursement, and any shift in government pricing power could crater earnings. The consensus is still Hold, not Buy, meaning most analysts aren’t convinced this rally is sustainable. At current valuations, the market is already pricing in the 2026 guidance, leaving little room for error.

What to Watch

Monitor DaVita’s 2026 quarterly earnings reports starting with Q1 results (likely April/May) to see if management actually delivers on that $13.60-$15.00 EPS guidance. Watch the Elara Caring and Mozarc Medical ventures closely — if these generate material revenue or margin accretion by late 2026, the bull case strengthens; if they’re just capital sinks, it weakens. Track Medicare reimbursement announcements and CMS policy changes, particularly around dialysis rates, since that’s the core business and any cuts would crater the stock. Keep an eye on the $160 resistance level on the chart; if DVA breaks above that decisively, the next target is likely $178+ (toward the 52-week high). Watch the debt-to-EBITDA ratio each quarter — if DaVita uses cash from operations to pay down debt rather than fund growth, that’s a sign management is cautious about the outlook. Finally, monitor analyst revisions over the next 60 days; if the consensus shifts from Hold to Buy after earnings season, it signals institutional conviction in the guidance.

Analyst Consensus

HOLD

Based on 8 analyst opinions

Low Target

$126.00

Mean Target

$151.50

High Target

$190.00

Earnings and Financial Data

Sector

Healthcare

Industry

Medical Care Facilities

Employees

N/A

Earnings & Dividends

Next Earnings

Feb 02, 2026

EPS (Trailing)

$9.51

Dividend Yield

None

Payout Ratio

Frequently Asked Questions

Is DVA a good stock to buy?

DVA is currently rated as a HOLD by analysts, with a target price of $151.50. Its P/E ratio of 14.78 suggests it’s reasonably valued, but with a forward P/E of 8.87, there might be better opportunities for growth elsewhere.

What is DVA’s price target?

Analysts have set a price target of $151.50 for DVA. This represents an upside potential of about 7.8% from its current price of $140.54.

Does DVA pay a dividend?

No, DaVita Inc. does not offer a dividend. Investors seeking income from dividends will need to look at other options as DVA reinvests profits back into the business.

What is DVA’s 52-week price range?

DVA has traded between $101.00 and $178.38 over the last 52 weeks. This volatility indicates the stock has potential for growth but also carries risks.

How does DVA’s market cap compare to its industry?

DaVita has a market cap of $9.39 billion, positioning it as a mid-cap within the healthcare sector. While it operates well in the medical care facilities industry, investors should consider larger or faster-growing companies for more aggressive strategies.

Related Stock Reports

Disclaimer: This report is for informational purposes only and does not constitute financial advice. The analysis and opinions expressed are those of AltStation.io and should not be relied upon as the sole basis for investment decisions. Always conduct your own research and consult with a qualified financial advisor before making investment decisions. Past performance does not guarantee future results. Updated February 07, 2026.